Johnson Financial Group Inc. Has $1.04 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Johnson Financial Group Inc. trimmed its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 12,791 shares of the biopharmaceutical company’s stock after selling 501 shares during the quarter. Johnson Financial Group Inc.’s holdings in Gilead Sciences were worth $1,036,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Altfest L J & Co. Inc. acquired a new position in shares of Gilead Sciences during the fourth quarter valued at about $210,000. Federated Hermes Inc. grew its position in Gilead Sciences by 4.9% in the 4th quarter. Federated Hermes Inc. now owns 3,787,355 shares of the biopharmaceutical company’s stock worth $306,814,000 after purchasing an additional 175,925 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in Gilead Sciences by 1.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 7,281,489 shares of the biopharmaceutical company’s stock worth $589,873,000 after purchasing an additional 87,482 shares in the last quarter. Wetzel Investment Advisors Inc. bought a new stake in Gilead Sciences in the 4th quarter worth about $74,000. Finally, ARGA Investment Management LP grew its position in Gilead Sciences by 6.2% in the 4th quarter. ARGA Investment Management LP now owns 635,058 shares of the biopharmaceutical company’s stock worth $51,446,000 after purchasing an additional 37,069 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD traded down $0.49 during trading on Friday, reaching $65.68. The company had a trading volume of 5,971,044 shares, compared to its average volume of 6,600,837. The company has a fifty day moving average of $68.45 and a two-hundred day moving average of $74.49. Gilead Sciences, Inc. has a 12 month low of $64.33 and a 12 month high of $87.86. The company has a current ratio of 1.08, a quick ratio of 0.94 and a debt-to-equity ratio of 1.31. The stock has a market capitalization of $81.83 billion, a P/E ratio of 182.44, a price-to-earnings-growth ratio of 1.32 and a beta of 0.22.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The company had revenue of $6.69 billion during the quarter, compared to analysts’ expectations of $6.36 billion. During the same period last year, the company posted $1.37 EPS. Gilead Sciences’s revenue was up 5.3% on a year-over-year basis. Equities research analysts forecast that Gilead Sciences, Inc. will post 3.74 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be given a dividend of $0.77 per share. The ex-dividend date is Friday, June 14th. This represents a $3.08 dividend on an annualized basis and a yield of 4.69%. Gilead Sciences’s dividend payout ratio (DPR) is currently 855.56%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. UBS Group reduced their price objective on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a research report on Wednesday, April 17th. Cantor Fitzgerald dropped their target price on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 7th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Friday, April 26th. Truist Financial cut shares of Gilead Sciences from a “buy” rating to a “hold” rating and dropped their target price for the company from $91.00 to $82.00 in a research note on Thursday, February 22nd. Finally, Royal Bank of Canada dropped their target price on shares of Gilead Sciences from $76.00 to $74.00 and set a “sector perform” rating on the stock in a research note on Friday, April 26th. Eleven analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $83.69.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the sale, the insider now directly owns 96,304 shares in the company, valued at approximately $7,026,339.84. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.16% of the stock is owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.